Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina

NCT03083119

Coronary Heart Disease Unstable Angina

UNKNOWN PHASE2

Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

NCT06863545

Coronary Artery Disease CT Angiography PCSK9 +1 more

RECRUITING NA

Study on the Registration of Coronary Heart Disease Patients Undergoing PCI

NCT02888652

Coronary Heart Disease

COMPLETED

Colchicine Use for Primary Prevention of Coronary Artery Disease

NCT05175274

Coronary Artery Disease

NOT_YET_RECRUITING PHASE3

Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI

NCT01293097

Non-ST Segment Elevation Myocardial Infarction Unstable Angina Pectoris Stable Angina Pectoris

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this multicenter, randomized, double-blind, placebo-controlled trial in patients with coronary heart disease,240 eligible patients aged ≥18 years will be randomized to receive placebo or Xuesaitong Soft Capsules(1.32g/d) and be followed up for 3 months. The primary endpoint of this study is hsCRP change from baseline to 3 months. The secondary endpoint is the changes of following indicators or scores from baseline to 3 months:(Ⅰ)other inflammation indicators except for hsCRP. (Ⅱ) inhibition of platelet aggregation; (Ⅲ)endothelial function indicators; (Ⅳ)blood lipid levels; (Ⅴ) seattle angina questionnaire score; (Ⅵ)36-item short form health survey score. The safety of using Xuesaitong soft capsules in patients with coronary heart disease will also be evaluated. The generalized linear mixed effects model will be used to evaluate the efficacy endpoint for the "full analysis set". For the safety analysis set, Chi-square test will be used to evaluate the safety endpoint.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xuesaitong Soft Capsule

Each participant in the Xuesaitong Soft Capsule treatment group will take a daily dose of 1.32g.

Group Type EXPERIMENTAL

Xuesaitong Soft Capsule

Intervention Type DRUG

Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.

Placebo

Each participant in the placebo group will take matching placebo.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Each participant in the placebo group will take matching placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xuesaitong Soft Capsule

Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.

Intervention Type DRUG

Placebo

Each participant in the placebo group will take matching placebo.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LixuwangⓇ

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years old
2. Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months:

1. History of myocardial infarction
2. Have received coronary interventional therapy
3. There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )
3. High-sensitivity C-reactive protein ≥2mg/L
4. Currently taking moderate or above intensity statins lipid-lowering drugs
5. Currently taking antiplatelet drugs
6. Sign informed consent

Exclusion Criteria

* Patients fulfilling any of the following criteria are not eligible for inclusion in this trial:

1. Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
2. Previously received coronary artery bypass grafting
3. Stroke occurred within the previous 3 months
4. Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction \< 35%
5. Revascularization or surgical procedures are planned within the next 3 months
6. Progressive neuromuscular disease, or creatine kinase (CK) levels \> 3 times the normal upper limit (ULN)
7. Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases
8. Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study
9. History of hereditary dyslipidemia such as familial hypercholesterolemia
10. There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan
11. History of symptomatic non-traumatic cerebral hemorrhage at any time in the past
12. History of gastrointestinal bleeding or major surgery within the past 6 months
13. Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month
14. There were clear adverse reactions to the main components of Xuesaitong in the past
15. Active liver disease, or alanine aminotransferase (ALT) levels \> 3 times the upper limit of normal (ULN)
16. Chronic kidney disease, or estimated glomerular filtration rate (eGFR) \<60ml/ (min×1.73m2)
17. Pregnancy or planned pregnancy, or breastfeeding
18. Malignant tumors, or other serious diseases with an estimated survival of less than 1 year
19. Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation
20. Have participated in or are participating in other clinical trials within the last 1 month
21. Poor adherence to follow-up or medication is known

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No